antiplatelet therapy over short periods of time in patients at acceptably low risk for bleeding, US guidelines are more reserved. 4, 5 To date, there have been limited data available to define current patterns of use of concomitant antiplatelet therapy along with OAC in AF patients in the United States. Furthermore, the risks of such combinations in community practice remain poorly defined.
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To address these important questions, we used data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) to investigate contemporary implementation of aspirin (ASA) therapy in patients with AF receiving OAC and associated clinical outcomes. Our objectives were to describe the overall use of concomitant antiplatelet and OAC therapy in AF patients, to identify clinical factors associated with concomitant therapy, to note the use of dual therapy among those without any known cardiovascular disease, and to determine whether the addition of antiplatelet therapy is associated with risk for subsequent bleeding events.
Methods
The ORBIT-AF registry is an observational study of outpatients with AF who are managed by primary care providers, cardiologists, and electrophysiologists. The design and rationale of the ORBIT-AF registry have been described previously. 6 Briefly, patients with ECG-proven AF ≥18 years of age who are able to provide informed consent and follow-up at least every 6 months are eligible for enrollment. Those with reversible causes of AF (eg, thyroid disease, postoperative AF) or patients with a life expectancy of <6 months are excluded.
This population was then stratified by the use of ASA: OAC alone versus dual therapy with OAC and ASA (OAC+ASA). Baseline characteristics, AF status, stroke and bleeding risk profiles, and vascular history were compared between these groups. Risk scores for stroke and bleeding risk were calculated, including the CHADS 2 , CHA 2 DS 2 -VASc, and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) scores. [7] [8] [9] To isolate the adjusted impact of concomitant ASA use separately from newer antiplatelet agents (clopidogrel, prasugrel), patients receiving other antiplatelet drugs were excluded.
In the entire study population, baseline characteristics associated with the use of OAC+ASA versus OAC alone were measured in multivariable modeling. In patients with 6-month follow-up (6540 of 7347, 89%), consistency of therapy was measured. Finally, 6-month clinical outcomes across all treatment groups were assessed and included death, first hospitalization by cause, bleeding events (major bleeding classified by International Society on Thrombosis and Haemostasis criteria 10 and minor bleeding), and ischemic events (myocardial infarction [MI], revascularization, stroke or non-central nervous system embolism, and transient ischemic attack). Additionally, absolute rates of ischemic and bleeding events are presented in high-risk subgroups.
Statistical Methods
Patient characteristics and outcomes are stratified by type of therapy. Continuous variables are presented as medians (interquartile range), and differences between the groups were assessed with the Kruskal-Wallis test. Categorical variables are presented as counts (proportions), and differences were assessed with the χ 2 test.
Hierarchical multivariable logistic regression was used, and odds ratios (ORs) and corresponding 95% confidence interval (CIs) were presented to assess factors associated with OAC+ASA (versus OAC alone) while accounting for variability in the use of dual therapy between sites. Backward selection was used to select from among the baseline characteristics, with an α for exclusion of 0.05, using hierarchical logistic regression. A shared frailty model was used to assess the association between of OAC+ASA (versus OAC alone) and 6-month outcomes, and hazard ratios and corresponding 95% CIs were presented. A shared frailty model was used to account for correlation between subjects from the same site. For nuisance bleeding, hierarchical logistic regression was used, and the OR and corresponding 95% CI were presented because the dates of events were not available. To minimize confounding, an adjusted regression model was developed by inverse weighting according to the propensity score for getting OAC+ASA. Propensity scores were calculated by use of a hierarchical logistic regression model adjusted for selected baseline characteristics. After backward selection with an α for exclusion of 0.10, the following variables were included in the propensity model: age, weight, creatinine clearance, diastolic blood pressure, sex (female), hyperlipidemia, liver disease, hypertension, diabetes mellitus, smoking, thyroid disease, previous gastrointestinal bleed, history of stroke or transient ischemic attack, history of coronary artery disease, peripheral arterial disease, coronary artery bypass grafting, percutaneous coronary intervention, drug-eluting stent, previous antiarrhythmic drug, previous interventional therapy for AF, renal disease, valvular disease, previous valve replacement or repair, level of education, ECG evidence of left ventricular hypertrophy, provider specialty, type of AF, and region. All continuous variables were tested for linearity, and nonlinear relationships were accounted for using linear splines. Analyses of the summary deidentified data were performed by the Duke Clinical Research Institute using SAS software (versions 9.3; SAS Institute, Cary, NC). All P values were 2 sided. The ORBIT-AF registry is approved by the Duke institutional review board, and all participating sites obtained institutional review board approval pursuant to local requirements. All subjects participating in ORBIT-AF provided written informed consent.
The authors had open access to the primary data and take full responsibility for the validity herein, as well as the formulation and drafting of the manuscript.
Results
The overall ORBIT-AF population included 10 126 patients enrolled at 176 sites from June 29, 2010, through August 29, 2011. For the purpose of this analysis, patients who were not taking an OAC were excluded. Additionally, patients on antiplatelet therapies other than ASA were excluded. This yielded a study population of 7347 patients from 174 sites ( Figure 1 ). More than one third of our study population (35%, n=2543) received concomitant ASA therapy. The dosing of ASA included 81 mg (n=2251 of 2543, 88.5%), 162 mg (n=12 of 2543, 0.5%), 325 mg (n=272 of 2543, 10.7%), and other doses (n=8 of 2543, 0.3%). Overall, dabigatran use was 6.9% in the OAC alone group (n=332 of 4804) and 6.0% in the OAC+ASA group (n=153 of 2543).
Factors Associated With Concomitant Aspirin
Baseline characteristics and medical history are shown in Table 1 . Patients receiving OAC+ASA therapy were slightly younger, were less likely to be female, but had more medical comorbidities, including hypertension, hyperlipidemia, diabetes mellitus, pulmonary disease, and heart failure, than patients receiving OAC alone. Rates of previous gastrointestinal bleeding were not significantly different (8.2% for OAC alone versus 7.1% for OAC+ASA; P=0.1). Patients receiving OAC+ASA were more likely to have new-onset or paroxysmal AF (4.6% versus 3.8% for new onset, 47% versus 45% for paroxysmal) versus long-standing persistent AF (30% versus 33%; P=0.003 for overall comparison; Table 2 ). Stroke risk scores were higher in patients receiving concomitant ASA (CHADS 2 ≥2 for 72% for OAC alone versus 79% for OAC+ASA; P<0.0001), whereas ATRIA bleeding risk scores were no different (17% with ATRIA score ≥5 in each group; P=0.7).
Vascular disease, including coronary, cerebral, or peripheral arterial disease, was common in the study cohort (Table 3) . Overall, 39% of patients receiving OAC+ASA had no history of atherosclerotic disease. Conversely, 37% of those on OAC alone had a history of atherosclerotic disease.
Multivariable factors associated with the use of additional ASA (versus OAC alone) are provided in Figure 2 . The strongest positive effect estimates were observed with a history of coronary artery disease (adjusted OR, 2.23; 95% CI, 1.82-2.73), previous maze procedure (adjusted OR, 1.56; 95% CI, ASA indicates aspirin; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVD, cerebrovascular disease; DES, drug-eluting stent; MI, myocardial infarction; OAC, oral anticoagulation; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; and TIA, transient ischemic attack.
P<0.0001 for all comparisons except MI in the previous year (P=0.003), DES in the previous year (P=0.004), nonhemorrhagic stroke (P=0.0001), and hemorrhagic stroke (P=0.3). 
Follow-Up Therapy and Outcomes
At 6-month follow-up, use rates of antithrombotic therapies were stable, with 89% of patients who started on OAC alone remaining on OAC alone and 81% of patients on OAC+ASA remaining on OAC+ASA. Characteristics of patients missing follow-up are shown in Table I in the online-only Data Supplement. Rates of major bleeding events at 6 months among high-risk subgroups are shown in Figure 3 . Unadjusted and multivariable-adjusted rates of major adverse outcomes at 6-months are shown in Table 4 . Major bleeding and bleeding hospitalization rates were significantly higher in the OAC+ASA group. There were 6 intracranial hemorrhage events in the OAC alone group versus 10 in the OAC+ASA group (0.14% versus 0.43%; P=0.02). After adjustment for baseline characteristics, major bleeding (hazard ratio, 1.53; 95% CI, 1.20-1.96) and bleeding hospitalization (hazard ratio, 1.52; 95% CI, 1.17-1.97) were more likely in patients receiving OAC+ASA (compared with OAC alone). Rates of ischemic events were low in both groups; MI occurred in 16 patients (0.38%) on OAC alone versus 11 patients on OAC+ASA (0.48%), coronary revascularization in 28 (0.66%) versus 31 (1.35%), stroke or non-central nervous system embolism in 18 (0.42%) versus 15 (0.65%), and transient ischemic attack in 7 (0.17%) versus 3 (0.13%).
For the subgroups of patients with previous MI or stroke/ transient ischemic attack, counts and rates of major adverse outcomes are shown in Table 5 . Further statistical comparisons of these populations were not performed because of low power.
Discussion
Of 7347 patients with AF taking OAC therapy, we found that 35% are also treated with ASA. Although those receiving concomitant ASA therapy were more likely to have previous cardiovascular disease, more than one third on concomitant ASA did not have any history of atherosclerotic disease. Furthermore, patients on combined OAC and ASA therapy had significantly higher adjusted rates of adverse clinical events, particularly bleeding events.
Recently, ASA therapy for the primary prevention of cardiovascular events has been questioned because the risks appear to outweigh the benefits in several important populations. 11 It is well appreciated that antiplatelet therapy increases the risk of major bleeding in patients with or without OAC therapy. [11] [12] [13] [14] [15] Previous work has demonstrated significant use of dual therapy with OAC and an antiplatelet in patients without manifest cardiovascular disease in a single-payer healthcare system, the Colorado Kaiser Permanente Healthcare System. 16 Our analysis extends these findings to a broad, national, community-based patient population. Our study also points out the lack of clear logic or pattern concerning who is being treated with OAC+ASA versus OAC alone. For example, we observed no difference in ATRIA bleeding scores between those receiving OAC alone and those on OAC+ASA; ≈25% of patients in both groups had elevated bleeding risk, with 17% in the highest-risk category (≥5). However, nearly 40% of patients in the OAC+ASA group lacked a convincing indication for ASA (manifest atherosclerotic disease), whereas 37% of patients on OAC alone had previous vascular disease. It is not clear that bleeding risk is being considered in the decision to use concomitant ASA.
The use of OAC+ASA appears to persist despite increasing concerns about the true bleeding risk of ASA and its lack of incremental benefit in preventing stroke in patients with AF already on OAC. 11 One meta-analysis comparing OAC and OAC+ASA identified an overall benefit only in patients receiving OAC for mechanical valves 17 ; the surfeit of bleeding events is a consistent finding across studies. 17, 18 Patients in our analysis receiving OAC+ASA had significantly higher rates of major bleeding events and higher rates of hospitalization for bleeding. These results persisted after multivariable adjustment of measured baseline characteristics, and mirror those seen in a previous international study. A claims-based study from Denmark found that ASA increased the risk for bleeding events nearly 2-fold relative to those on warfarin alone. 15 When previously published data on ischemic outcomes are combined with the present analysis demonstrating increased bleeding, the available evidence suggests that concomitant antiplatelet therapy is associated with increased risk and minimal evidence of benefit. 15, 19 The use of antiplatelet therapy alone for secondary prevention in patients with a history of cardiovascular disease has been demonstrated to improve outcomes within an acceptable risk profile 12 and remains a practice recommendation from the American College of Cardiology/American Heart Association guidelines. 20 However, its use in patients with AF who are also treated with OAC is less clear and is not supported by randomized trials. Patients with AF and coronary artery disease have an increased risk of adverse events, including mortality, compared with patients with coronary artery disease without AF. 3 Yet those on OAC had a low risk of MI when treated with an OAC in recent randomized study populations (range, 0.5%-1.1%). 21, 22 Furthermore, several trials in patients without AF have demonstrated equal or superior efficacy of OAC versus ASA for the secondary prevention of ischemic events in patients with MI. [23] [24] [25] Finally, preliminary data from the only randomized trial of dual therapy (OAC+clopidogrel) versus triple therapy (OAC plus ASA and clopidogrel) in patients undergoing percutaneous coronary intervention demonstrated a significant reduction in bleeding events in the dual therapy group. 26
Limitations
These data represent observations from a prospective, national registry; thus, they are subject to the limitations inherent in such methods, including site participation, patient selection, and reporting biases. Furthermore, the defined treatment groups (OAC alone and OAC+ASA) were not randomly assigned, and there are important differences in ischemic and bleeding risk levels between these 2 populations. Regression analyses cannot completely adjust for such differences; therefore, comparisons of outcomes in these groups are likely limited by residual bias. Additionally, low rates of previous and incident ischemic events (stroke or MI) limit the ability to detect meaningful differences in these end points. Finally, every attempt was made to capture ASA therapy, regardless of prescription or over-the-counter use. Aspirin use was ascertained on follow-up and includes both prescription and over-the-counter use; however, these data could potentially be susceptible to recall bias.
Conclusions
Patients with AF prescribed OAC therapy are often also treated with concomitant ASA, even when they do not have vascular disease. Furthermore, patients with AF and known cardiovascular disease are often treated with OAC alone. The use of OCA+ASA was independently associated with significantly increased risk for bleeding compared with the use of OCA alone. The optimal antithrombotic strategy for patients with AF remains unclear. These and other data raise the possibility that a less is more strategy may be favorable among AF patients on OAC. 27 However, we believe adequately powered, prospective clinical studies of these regimens are warranted to definitely assess the benefit or harm of such strategies. In the interim, clinicians need to carefully weigh whether the potential benefits of adding ASA are worth the risk among patients with AF on OAC. In lieu of clinical trials, automated risk assessment tools that calculate ischemic risk and bleeding risk might help guide concomitant antiplatelet therapy.
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OAC+ASA: oral anticoagulation and aspiring therapy; LVEF: left-ventricular ejection fraction;
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